文献速递神经重症与神经感染

COVID-19合并急性脑病与昏迷患者的结局:一项国际前瞻性研究

Outcomes in Patients With COVID-19 With Acute Encephalopathy and Coma: An International Prospective Study.
PubMed 文献 · Neurology · 2023-04-11

该国际前瞻性研究在6个国家31个大学附属ICU前瞻性收集2020年3月至9月重症COVID-19合并急性脑病成人患者数据,评估90天结局。4060例COVID-19住院患者中374例(9.2%)在ICU入科时或之前出现急性脑病,199/345例(57.7%)90天结局不良。多变量分析显示年龄>70岁、 presumed fatal合并症、入ICU前/时GCS<9、血管活性药支持、肾脏替代治疗及CNS缺血/出血并发症与不良结局独立相关。

要点

  • 重症COVID-19患者中急性脑病发生率为9.2%(374/4060)。
  • 急性脑病患者90天不良结局(GOS-E 1-4)比例为57.7%(199/345)。
  • 年龄>70岁、GCS<9、血管活性药支持等与不良结局独立相关。

核心结论

  • 重症COVID-19患者ICU入科时急性脑病患病率较低,但合并急性脑病者超过半数90天结局不良。

研究设计与样本

  • 国际前瞻性观察性研究,纳入6个国家31个大学或大学附属ICU的成年重症COVID-19合并急性脑病患者,收集时间为2020年3月至9月。
  • 急性脑病定义为亚综合征性谵妄、谵妄或严重意识下降导致的昏迷状态。
  • 采用多变量logistic回归分析90天结局相关因素,GOS-E评分1-4分定义为不良结局。
  • 研究注册号ClinicalTrials.gov NCT04320472。

主要发现

  • 4060例COVID-19住院患者中374例(9.2%)在ICU入科时或之前出现急性脑病。
  • 345例可评估患者中199例(57.7%)90天GOS-E评估为不良结局(29例失访)。
  • 年龄>70岁(OR 4.01,95%CI 2.25-7.15)、 presumed fatal合并症(OR 3.98,95%CI 1.68-9.44)、入ICU前/时GCS<9(OR 2.20,95%CI 1.22-3.98)与不良90天结局独立相关。
  • ICU期间血管活性药/正性肌力药支持(OR 3.91,95%CI 1.97-7.76)、肾脏替代治疗(OR 2.31,95%CI 1.21-4.50)、CNS缺血或出血并发症作为急性脑病病因(OR 3.22,95%CI 1.41-7.82)与不良90天结局独立相关。
  • 癫痫持续状态、后部可逆性脑病综合征和可逆性脑血管收缩综合征与较低的不良90天结局风险相关(OR 0.15,95%CI 0.03-0.83)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To report the prevalence of acute encephalopathy and outcomes in patients with severe coronavirus disease 2019 (COVID-19) and to identify determinants of 90-day outcomes. METHODS: Data from adults with severe COVID-19 and acute encephalopathy were prospectively collected for patients requiring intensive care unit management in 31 university or university-affiliated intensive care units in 6 countries (France, United States, Colombia, Spain, Mexico, and Brazil) between March and September of 2020. Acute encephalopathy was defined, as recently recommended, as subsyndromal delirium or delirium or as a comatose state in case of severely decreased level of consciousness. Logistic multivariable regression was performed to identify factors associated with 90-day outcomes. A Glasgow Outcome Scale-Extended (GOS-E) score of 1-4 was considered a poor outcome (indicating death, vegetative state, or severe disability). RESULTS: Of 4,060 patients admitted with COVID-19, 374 (9.2%) experienced acute encephalopathy at or before the intensive care unit (ICU) admission. A total of 199/345 (57.7%) patients had a poor outcome at 90-day follow-up as evaluated by the GOS-E (29 patients were lost to follow-up). On multivariable analysis, age older than 70 years (odds ratio [OR] 4.01, 95% CI 2.25-7.15), presumed fatal comorbidity (OR 3.98, 95% CI 1.68-9.44), Glasgow coma scale score <9 before/at ICU admission (OR 2.20, 95% CI 1.22-3.98), vasopressor/inotrope support during ICU stay (OR 3.91, 95% CI 1.97-7.76), renal replacement therapy during ICU stay (OR 2.31, 95% CI 1.21-4.50), and CNS ischemic or hemorrhagic complications as acute encephalopathy etiology (OR 3.22, 95% CI 1.41-7.82) were independently associated with higher odds of poor 90-day outcome. Status epilepticus, posterior reversible encephalopathy syndrome, and reversible cerebral vasoconstriction syndrome were associated with lower odds of poor 90-day outcome (OR 0.15, 95% CI 0.03-0.83). DISCUSSION: In this observational study, we found a low prevalence of acute encephalopathy at ICU admission in patients with COVID-19. More than half of patients with COVID-19 presenting with acute encephalopathy had poor outcomes as evaluated by GOS-E. Determinants of poor 90-day outcome were dominated by older age, comorbidities, degree of impairment of consciousness before/at ICU admission, association with other organ failures, and acute encephalopathy etiology. TRIAL REGISTRATION INFORMATION: The study is registered with ClinicalTrials.gov, number NCT04320472.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Legriel S, Badenes R, Engrand N, et al. Outcomes in Patients With COVID-19 With Acute Encephalopathy and Coma: An International Prospective Study. Neurology. 2023. PMID: 37041081. doi:10.1212/WNL.0000000000207263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。